Together we strive, Together we stride

Strides is led and driven by its expertise in Research and Development, visible through its success in creating niche and differentiated products portfolio. Our Global Formulation R&D center at Bangalore drives high value product delivery via latest technology platforms. Strides R&D is imbibed with continuous learning and innovation and is actively engaged in the development of a wide range of dosage forms with special emphasis on novel drug delivery systems for solid orals (modified release tablets and capsules) and soft gelatin capsules for both Regulated and Emerging markets. Our product selection for development is mainly focussed on niche products characterized by complex formulations across diverse therapeutic segments.

With over 200 plus scientists, the R&D team offers solutions across the entire product development value chain including strategic sourcing, IP management, formulation development, analytical method development and validation, technology transfer, bio-equivalence, toxicological studies, packaging development and global regulatory submissions. Our R&D facility is equipped with state-of-art infrastructure that supports all our research activities including complex formulations development under one roof.

Our strong formulation R&D capabilities combined with knowledge of the regulatory environment in Regulated markets have resulted in successful product registrations in several markets. Strides holds about 80 ANDAs (Abbreviated New Drug Applications) with US Food & Drug Administration (FDA) and have received approvals for 44 ANDAs. In addition to these, Strides have also secured 17 tentative ANDA approvals filed under PEPFAR (President’s Emergency Plan for Aids Relief) program. There are about 1000 plus authorisations across other Global Markets in different geographies that includes 200 Marketing Authorisations in other Regulated markets like Australia, Canada and European countries.

Our current pipeline includes Para - IV First to File ANDAs and high potential products identified for early launch opportunities in US Market.

  • Technical Expertise

    Strong technical leadership to develop high-quality pharma products that create strategic value for our partners and customers

  • Product Selection

    Focus on niche products characterized by complex formulations across diverse therapeutic categories

  • Development

    R&D capability to develop Finished Dosage Forms with latest technologies at competitive cost

  • Regulatory Review/Filing

    Strong IP assessment capabilities and global regulatory expertise